Shares of Eli Lilly fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. Shares of Eli Lilly (NYSE: ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly’s first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday ...

LLY has delivered impressive returns of 15% year-to-date, outperforming the S&P 500’s 5% decline during the same period. This ...

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts.

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...